Steris: May Benefit From Bringing Pharmaceutical Manufacturing Back To The U.S.

Group 1 - The stock price of Steris plc (NYSE: STE) has increased by more than 11% since the upgrade to a Strong Buy rating in March 2025 [1] - The company is expected to benefit from potential market conditions influenced by political factors [1]